Cargando…
208 Identification of Trichomonas vaginalis 5-nitroimidazole resistance targets to inform future drug development
OBJECTIVES/GOALS: 5-nitroimidazoles are the only FDA-approved medications for T. vaginalis treatment. Resistance has been observed in 5-10% of cases, but may be rising. We aimed to delineate mechanisms of resistance in isolates of T. vaginalis using transcriptome profiling of resistant and sensitive...
Autores principales: | Graves, Keonte, Sharma, Jyoti, Reily, Colin, Tiwari, Hemant, Srinivasasainagendra, Vinodh, Secor, W. Evan, Novak, Jan, Muzny, Christina A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209190/ http://dx.doi.org/10.1017/cts.2022.110 |
Ejemplares similares
-
Identification of Trichomonas vaginalis 5-Nitroimidazole Resistance Targets
por: Graves, Keonte J., et al.
Publicado: (2023) -
New test for sensitivity evaluation of Trichomonas vaginalis to nitroimidazoles and nitrofurans in vitro
por: Makhlay, NS
Publicado: (2011) -
In Vitro Effect of 5-Nitroimidazole Drugs against Trichomonas vaginalis Clinical Isolates
por: Mtshali, Andile, et al.
Publicado: (2022) -
Nitroimidazole carboxamides as antiparasitic agents targeting Giardia lamblia, Entamoeba histolytica and Trichomonas vaginalis
por: Jarrad, A.M., et al.
Publicado: (2016) -
Recent advances in the epidemiology, diagnosis, and management of
Trichomonas vaginalis infection
por: Van Gerwen, Olivia T., et al.
Publicado: (2019)